Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Mar 06, 2015 4:11pm
160 Views
Post# 23499006

RE:Various questions and observations from a newbie

RE:Various questions and observations from a newbieHi tundup. Thanks for the focused and relevant questions and welcome on board.

It is always very helpful when someone comes in with fresh questions because it provides new perspectives as well as reminds me of all of the positive events and discoveries I have seen re RVX since joining the postings.

I believe most of your questions have been addressed.

I want to thank you for
  1. Your perspective on the RVX valuation (your point 5) and the framework you have provided on the broader market. I think many of us wonder about the low valuation placed on RVX and some of these have been mentioned today. Now, with the Emerald Logics FACET analysis complete there may emerge new findings and understanding regarding predictive modelling of why rvx-208 reduces MACE and findings about the underlying biochemical pathways which can be used to interest BP even before the BETonMACE trial is complete.
  2. Clarification of the share dilution of RVX regarding Zenith.
  3. Clarification of the Zenith royalties.

Thanks also the very informative posts today by Jkj, GV, fouremm, BearDownAZ and the market oriented posters.

Further clarification of the continuing trial related to CETP was helpful but also for me (a non science person...but an amateur science junkie) and reinforces my belief in the BET approach.

I'm tempted to explain more about the power of the FACET analysis but I'll leave it to a different time. Suffice it to say that the fact that RVX did this is a very progressive and beneficial move that could significantly accelerate the understanding of rvx-208. 

GLTA
Cheers
Toinv   :)
Bullboard Posts